Kamataki T - Search Results

1

CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.

Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y. Fujita K, et al. Among authors: kamataki t. Cancer Sci. 2008 May;99(5):1049-54. doi: 10.1111/j.1349-7006.2008.00773.x. Cancer Sci. 2008. PMID: 18380793 Free PMC article. Clinical Trial.

2

Screening of organosulfur compounds as inhibitors of human CYP2A6.

Fujita K, Kamataki T. Fujita K, et al. Among authors: kamataki t. Drug Metab Dispos. 2001 Jul;29(7):983-9. Drug Metab Dispos. 2001. PMID: 11408364

3

Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.

Fujita K, Kamataki T. Fujita K, et al. Among authors: kamataki t. Mutat Res. 2001 Nov 1;483(1-2):35-41. doi: 10.1016/s0027-5107(01)00223-8. Mutat Res. 2001. PMID: 11600130

4

Preclinical approach for identifying drug interactions.

Kamataki T, Yokoi T, Fujita K, Ando Y. Kamataki T, et al. Cancer Chemother Pharmacol. 1998;42 Suppl:S50-3. doi: 10.1007/s002800051079. Cancer Chemother Pharmacol. 1998. PMID: 9750029 Review.

5

Genetic polymorphism of CYP2A6 in relation to cancer.

Kamataki T, Nunoya K, Sakai Y, Kushida H, Fujita K. Kamataki T, et al. Mutat Res. 1999 Jul 16;428(1-2):125-30. doi: 10.1016/s1383-5742(99)00040-x. Mutat Res. 1999. PMID: 10517986

6

Mutagenesis testing based on bacterial expression of human P450s.

Kamataki T, Fujita K. Kamataki T, et al. Methods Enzymol. 2002;357:301-10. doi: 10.1016/s0076-6879(02)57688-6. Methods Enzymol. 2002. PMID: 12424920 No abstract available.

7

Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.

Kamataki T, Fujita K, Nakayama K, Yamazaki Y, Miyamoto M, Ariyoshi N. Kamataki T, et al. Drug Metab Rev. 2002 Aug;34(3):667-76. doi: 10.1081/dmr-120005668. Drug Metab Rev. 2002. PMID: 12214673 Review.

8

Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase: prediction of metabolism and toxicity of drugs in humans.

Fujita K, Kamataki T. Fujita K, et al. Among authors: kamataki t. Drug Metab Pharmacokinet. 2002;17(1):1-22. doi: 10.2133/dmpk.17.1. Drug Metab Pharmacokinet. 2002. PMID: 15618648 Free article.

9

Overexpression of CYP2A6 in human colorectal tumors.

Matsuda Y, Saoo K, Yamakawa K, Yokohira M, Suzuki S, Kuno T, Kamataki T, Imaida K. Matsuda Y, et al. Among authors: kamataki t. Cancer Sci. 2007 Oct;98(10):1582-5. doi: 10.1111/j.1349-7006.2007.00572.x. Epub 2007 Aug 7. Cancer Sci. 2007. PMID: 17683511 Free PMC article.

10

Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase.

Fujita K, Kamataki T. Fujita K, et al. Among authors: kamataki t. Environ Mol Mutagen. 2001;38(4):339-46. doi: 10.1002/em.10036. Environ Mol Mutagen. 2001. PMID: 11774366

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

413 results

Search Page

Filters